Dr. Kevin AlessandriCo-founder, Chief Technology Officer & US VP, TreeFrog Therapeutics
Kévin earned a degree in biochemistry, a Masters in system biology and a diploma in neurobiology from the Ecole Nationale Supérieure before focusing on biophysics for his PhD, completing his thesis on micro-fluidic technologies for cell encapsulation at the Institut Curie, Paris, France.
He continued his research with a post-doctoral fellowship at the University of Geneva, Switzerland, centered on pluripotent cells, tissue engineering and neurogenerative diseases.
Kevin worked for the last 15 years in 3D encapsulation leading to 12 papers more than 1000 citations and filed 14 patents. It was during his time in Geneva that the fortuitous meeting with fellow scientist Maxime Feyeux, led to the subsequent development of a 3D print encapsulation system in 2015 and the invention of the biomimetic C-Stem™ technology that TreeFrog Therapeutics is based upon. The promise of the technology, together with the passion of the duo led to numerous awards and grants and TreeFrog Therapeutics was incorporated in 2018 with the mission to provide innovative, safe and more affordable cell therapy to all through proprietary therapeutic programs and external partnerships.
Following a $75M Series B financing in 2021, Kévin Alessandri moved to Boston, MA, in 2022 to lead the U.S. subsidiary of TreeFrog Therapeutics.
Source: https://treefrog.fr/ips-stem-cell-therapy-biotech-company/
